PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: **A3** (11) International Publication Number: WO 00/12678 09 March 2000 (09.03,2000) C12N 15/31, C07K 14/31, (43) International Publication Date: C12N 1/21, C12N 15/63, C12N 15/66 (21) International Application Number: PCT/US99/19726 Published (22) International Filing Date: 31 August 1999 (31.08.1999) (30) Priority Data: 01 September 1998 (01.09.1998) US 60/098,964 (60) Parent Application or Grant HUMAN GENOME SCIENCES, INC. [/]; (). BAILEY, Camella, C. [/]; (). CHOI, Gil, H. [/]; (). BAILEY, Camella, C. [/]; (). CHOI, Gil, H. [/]; (). HOOVER, Kenley, K.; ().

(54) Title: STAPHYLOCOCCUS AUREUS GENES AND POLYPEPTIDES

(54) Titre: GENES DE STAPHYLOCOCCUS AUREUS ET POLYPEPTIDES ASSOCIES

(57) Abstract

The present invention relates to novel genes from S. aureus and the polypeptides they encode. Also provided are vectors, host cells, antibodies and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of S. aureus polypetide activity. The invention additionally relates to diagnostic methods for detecting Staphylococcus nucleic acids, polypeptides and antibodies in a biological sample. The present invention further relates to novel vaccines for the prevention or attenuation of infection by Staphylococcus.

(57) Abrégé

La présente invention concerne de nouveaux gènes provenant de S. aureus et les polypeptides qu'ils codent. On décrit également des vecteurs, des cellules hôtes, des anticorps et des procédés de recombinaison utilisés pour produire ces derniers, ainsi que des procédés de criblage permettant d'identifier des agonistes et des antagonistes de l'activité du polypeptide S. aureus. L'invention concerne en outre des procédés de diagnostic utiles pour détecter des acides nucléiques, des polypeptides et des anticorps de Staphylococcus dans un échantillon biologique, ainsi que de nouveaux vaccins permettant de prévenir ou d'atténuer l'infection par le Staphylococcus.

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| 51) International Patent Classification 7: | | (11) International Publication Number: WO 00/1267 |
|---|---|---|
| C12N 15/31, 15/66, 15/63, 1/21, C07K 14/31 | A3 | (43) International Publication Date: 9 March 2000 (09.03.0 |
| 22) International Application Number: PCT/US 22) International Filing Date: 31 August 1999 (2) 30) Priority Data: 60/098,964 1 September 1998 (01.09.9) 71) Applicant (for all designated States except US): GENOME SCIENCES, INC. [US/US]; 9410 (2) Avenue, Rockville, MD 20850 (US). 72) Inventors/Applicants (for US only): BAILEY, Ca [US/US]; 1753 Kilbourne Place NW, Washin 20010 (US). CHOI, Gil, H. [CN/US]; 11429 Pote Drive, Rockville, MD 20850 (US). | (31.08.9 8) U HUMA Key Wo amella, | BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GGH, GM, HR, HU, ID, IL, IN, IS, IP, KE, KG, KP, KKZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SI, SI, TI, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FR, GB, GR, IE, TT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NSN, TD, TG). Published With international search report. |
| (74) Agents: HOOVER, Kenley, K. et al.; Human Genome Inc., 9410 Key West Avenue, Rockville, MD 201 | | |
| ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | 000 (00 | |
| | | |
| (54) Title: <i>STAPHYLOCOCCUS AUREUS</i> GENES ANI (57) Abstract | | |
| (54) Title: STAPHYLOCOCCUS AUREUS GENES AND (57) Abstract The present invention relates to novel genes from S antibodies and recombinant methods for producing the sar antiponists of S. aureus polypetide activity. The inventic | D POLY S. aureu ne. Theon addit | |
| (54) Title: STAPHYLOCOCCUS AUREUS GENES AND (57) Abstract The present invention relates to novel genes from 3 antibodies and recombinant methods for producing the sar antigonists of S. aureus polypetide activity. The inventic acids, polypeptides and antibodies in a biological sample | D POLY S. aureu ne. Theon addit | PEPTIDES s and the polypeptides they encode. Also provided are vectors, host or invention further relates to screening methods for identifying agonists onally relates to diagnostic methods for detecting Staphylococcus nuc |
| (54) Title: STAPHYLOCOCCUS AUREUS GENES AND (57) Abstract The present invention relates to novel genes from 3 antibodies and recombinant methods for producing the sar antigonists of S. aureus polypetide activity. The inventic acids, polypeptides and antibodies in a biological sample | D POLY S. aureu ne. Theon addit | PEPTIDES s and the polypeptides they encode. Also provided are vectors, host or invention further relates to screening methods for identifying agonists onally relates to diagnostic methods for detecting Staphylococcus nuc |
| (54) Title: STAPHYLOCOCCUS AUREUS GENES AND (57) Abstract The present invention relates to novel genes from 3 antibodies and recombinant methods for producing the sar antigonists of S. aureus polypetide activity. The inventic acids, polypeptides and antibodies in a biological sample | D POLY S. aureu ne. Theon addit | PEPTIDES s and the polypeptides they encode. Also provided are vectors, host or invention further relates to screening methods for identifying agonists onally relates to diagnostic methods for detecting Staphylococcus nuc |
| (54) Title: STAPHYLOCOCCUS AUREUS GENES AND (57) Abstract The present invention relates to novel genes from 3 antibodies and recombinant methods for producing the sar antigonists of S. aureus polypetide activity. The inventic acids, polypeptides and antibodies in a biological sample | D POLY S. aureu ne. Theon addit | PEPTIDES s and the polypeptides they encode. Also provided are vectors, host or invention further relates to screening methods for identifying agonists onally relates to diagnostic methods for detecting Staphylococcus nuc |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| AL | Albania | ES | Spain | LS | Lesotho | SI | Slovenia |
|----|--------------------------|-----|---------------------|----|-----------------------|----|--------------------------|
| AM | Armenia | FI | Finland | LT | Lithuania | SK | Slovakia |
| AT | Austria | FR | France | LU | Luxembourg | SN | Senegal . |
| AU | Australia | GA | Gabon | LV | Latvia | SZ | Swaziland |
| ۸Z | Azerbaijan | CB | United Kingdom | MC | Monaco | TD | Chad |
| BA | Bosnia and Herzegovina | GE | Georgia | MD | Republic of Moldova | TG | Togo |
| BB | Barbados | GH | Ghana | MG | Madagascar | TJ | Tajikistan |
| BE | Belgium | GN | Guinca | MK | The former Yugoslav | TM | Turkmenistan |
| BF | Burkina Faso | GR | Greece | | Republic of Macedonia | TR | Turkey |
| BG | Bulgaria | HU | Hungary | ML | Mali | TT | Trinidad and Tobago |
| BJ | Benin | ΙE | Ireland | MN | Mongolia | UA | Ukraine |
| BR | Brazil | IL | Israel | MR | Mauritania | UG | Uganda |
| BY | Belarus | IS | Iceland | MW | Malawi | US | United States of America |
| CA | Canada | lT | İtaly | MX | Mexico | UZ | Uzbekistan |
| CF | Central African Republic | JP | Japan | NE | Niger | VN | Viet Nam |
| CG | Cango | KE | Kenya | NL | Netherlands | YU | Yugoslavia |
| CH | Switzerland | KG | Kyrgyzstan | NO | Norway | ZW | Zimbabwe |
| CI | Côte d'Ivoire | KP | Democratic People's | NZ | New Zealand | | |
| CM | Camercon | | Republic of Korea | PL | Poland | | |
| CN | China | KR | Republic of Korea | PT | Portugal | | |
| CU | Cuba | KZ. | Kazakstan | RO | Romania | | |
| CZ | Czech Republic | LC | Saint Lucia | RU | Russian Federation | | |
| DE | Germany | LI | Liechtenstein | SD | Sudan | | |
| DK | Denmark | LK | Sri Lanka | SE | Sweden | | |
| EE | Estonia | LR | Liberia | SG | Singapore | | |

INTERNATI NAL SEARCH REP RT

International application No. PCT/US99/19726

| | | | | 1 | | |
|--|---|---------------------------|--|------------------------------------|--|--|
| A. CLASSIFICATION OF SUBJECT MATTER | | | | | | |
| | :C12N 15/31,15/66, 15/63, 1/21: C07K 14/31 | | | | | |
| | :536/23.7; 435/91.41, 320.1, 252.3, 69.1; 530/350 to International Patent Classification (IPC) or to both | national classification | and IPC | | | |
| | DS SEARCHED | | | | | |
| Minimum d | ocumentation searched (classification system follower | d by classification sy | mbols) | | | |
| U.S. : | 536/23.7; 435/91.41, 320.1, 252.3, 69.1; 530/350 | · | | | | |
| Documentat | Documentation occrehed other than minimum documentation to the extent that such documents are included in the fields searched | | | | | |
| Genbank | Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Genbank, Swissprot, PIR60, SPTREMBL9 search terms: sequences corresponding to SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 | | | | | |
| | | 0, 8, 10, 12, 14, 16, | 16, and 20 | | | |
| | UMENTS CONSIDERED TO BE RELEVANT | | | | | |
| Category | Citation of document, with indication, where a | ppropriate, of the rela | vant passages | Relevant to claim No. | | |
| х | EP 0 843 016 A2 (SMITHKLINE BEECHAM CORPORATION) 20 1-11 May 1998, page 23 (relevant to instant SEQ ID NO:16). | | | | | |
| x | EP 0 811 696 A2 (SMITHKINE BEECHAM CORPORATION) 10 December 1997, page 8 (relevant to instant SEQ ID NO: 12). | | | | | |
| х | EP 0 826 774 A2 (SMITHKINE BEE March 1998, Figure 1 (relevant to ins | CHAM CORPORTION SEQ ID NO | RATION) 14): 6). | 1-11 | | |
| Purth | er documents are listed in the continuation of Box (| Sec pate: | nt family annex. | | | |
| | ecial categories of cited documents: | | | ernational filing data or priority | | |
| *A* doc | pumont defining the general state of the art which is not considered be of particular relevance | date and not i | n conflict with the appl or theory underlying the | ication but cited to understand | | |
| | fier document published on or after the international filing date | "X" document of | particular relevance; th | e claimed invention cannot be | | |
| "I." dos | 1." document which may throw doubts an priority claim(s) or which is cited to establish the publication date of another citation or other | | | | | |
| I pe | special reason (as specified) "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive dep when the document is | | | | | |
| m.e | occument reterring to an oral disclosure, use, exhibition or other combined with one or more other such documents, such combination being obvious to a person skilled in the art | | | | | |
| "P" document published prior to the international filing date but later than "&" document member of the same patent family the priority date claimed | | | | | | |
| Date of the actual completion of the international search 10 FEBRUARY 2000 Date of mailing of the international search report 0 6 APR 2006 | | | | | | |
| 10 FEBRUARY 2000 Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Date of mailing of the international search report Authorized officer JOHN S. BRUSCA Authorized officer JOHN S. BRUSCA | | | | | | |
| | Pacsimile No. (703) 305-3230 Telephone No. (703) 308-0196 | | | | | |

Form PCT/ISA/210 (second sheet)(July 1992)☆

INTERNATIONAL SEARCH REPORT

International application No. PCT/US99/19726

| Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) | | | | | | |
|---|--|--|--|--|--|--|
| This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: | | | | | | |
| 1. Claims Nos.: because they relate to subject matter not required to be scarched by this Authority, namely: | | | | | | |
| Claims Nos.: because they relate to parts of the international application that do not comply an extent that no meaningful international search can be carried out, specifically an extent that no meaningful international search can be carried out, specifically as a search can be car | with the prescribed requirements to such ically: | | | | | |
| Claims Nos.: because they are dependent claims and are not drafted in accordance with the se | econd and third sentences of Rule 6.4(a). | | | | | |
| Box 11 Observations where unity of invention is lacking (Continuation of item 2 of first sheet) | | | | | | |
| This International Searching Authority found multiple inventions in this international application, as follows: | | | | | | |
| Please See Extra Sheet. | | | | | | |
| | | | | | | |
| • | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| 1. As all required additional search fees were timely paid by the applicant, this in claims. | ternational search report covers all searchable | | | | | |
| 2. As all searchable claims could be searched without effort justifying an addition of any additional fee. | onal fee, this Authority did not invite payment | | | | | |
| 3. As only some of the required additional search fees were timely paid by the ap only those claims for which fees were paid, specifically claims Nos.: | plicant, this international search report covers | | | | | |
| | | | | | | |
| | | | | | | |
| No required additional search fees were timely paid by the applicant. Con restricted to the invention first mentioned in the claims; it is covered by claims: 1-11 | sequently, this international search report is ims Nos.: | | | | | |
| Remark on Protest The additional search fees were accompanied by t | he applicant's protest. | | | | | |
| No protest accompanied the payment of additional | | | | | | |

Form PCT/ISA/210 (continuation of first sheet(1))(July 1992)*

INTERNATI NAL SEARCH REPORT

International application No. PCT/US99/19726

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1-11, drawn to Staphylococcal nucleic acids, proteins encoded by the nucleic acids, vectors comprising the nucleic acids, methods of making the vectors, cells comprising the vectors, and methods of expressing the nucleic acids in transformed cells.

Group II, claims(s) 12 and 13, drawn to an antibody and a cell producing an antibody, both antibodies being specific for the protein encoded by the nucleic acids of Group I.

Group III, claim(s) 16, drawn to a vaccine comprising a protein encoded by the nucleic acids of Group I.

Group IV, claim(s)17, drawn to a method of preventing an infection by administration of a protein encoded by the nucleic acids of Group I.

Group V, claim(s) 18, drawn to a Staphylococcal nucleic acid asaay using the nucleic acids of Group I as probes.

Group VI, claim(s) 19, drawn to an assay of antibodies specific for Staphylococcal proteins using proteins encoded by the nucleic acids of Group I.

Group VII, claim 20, drawn to an assay of the Staphylococcal proteins of Group I using antibodies specific for the proteins of Group I.

The inventions listed as Groups I-VII do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: Groups II-VII constitute the third product, and the second through fifth methods of use of the products of Group I. PCT Rule 13.1 and Annex B do not show that unity of invention exists between a first and second product or method of use.

This application contains claims directed to more than one species of the generic invention. These species are deemed to lack Unity of Invention because they are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for more than one species to be searched, the appropriate additional search fees must be paid. The species are as follows:

The amino acid sequences of the polypeptides shown in Table 1.

The claims are deemed to correspond to the species listed above in the following manner:

All claims of each Group discussed above are drawn to the species indicated above.

The following claims are generic: Claims 1-20

The species listed above do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: Each species is drawn to a different amino acid sequence, and to nucleic acids encoding different amino acid sequences. There is no disclosed relationship between the sequences of each individual species disclosed in Table 1.

Restriction to a single species has been waived sua sponte and the Applicants are permitted to have ten species examined without payment of additional fees. The Applicant's representative Kenley Hoover elected telephonically on 1/27/00 to have the sequences corresponding to SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, and 20 examined.